Drug Trial Radar · NCT07270835
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 1, 2025
Primary completion
Apr 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.
Conditions
- Hemophagocytic Lymphohistiocytosis
- B Cell Lymphoma
Interventions
RituximabDrug
375 mg/m², intravenously, once weekly for 4 weeks
ZanubrutinibDrug
160 mg, orally, twice daily for 4 weeks as for rutuximab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- response rate of HLH after 4 weeks of treatmentTime frame: after 4 weeks
- OS at week 8Time frame: after 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.